Neuronetics, Inc., founded in 2003 and headquartered in Malvern, PA, develops non-invasive therapies for chronic neuro health disorders. The company's flagship product, NeuroStar Transcranial Magnetic Stimulation (TMS), offers a safe and effective treatment for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression. NeuroStar TMS provides focused, localized treatment without the side effects associated with medication, making it a valuable option for patients seeking alternative therapies.
Neuronetics has achieved significant milestones, including FDA clearance for NeuroStar TMS in treating MDD, OCD, and anxious depression. The company is publicly traded on Nasdaq under the ticker symbol STIM and is a component of the Russell 2000 Index. Key figures in the organization include President and CEO Keith J. Sullivan and CFO Stephen Furlong. Neuronetics' innovative approach to mental health treatment has had a substantial impact on improving the quality of life for patients with chronic neuro health disorders.
